Cleo Diagnostics Ltd logo

Cleo Diagnostics Ltd (COV)

Market Closed
CXA CXA
- Market Cap
- P/E Ratio
- Div Yield
32 Volume
- Eps
Want to track COV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

COV is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on one exchange.

Cleo Diagnostics Ltd (COV) FAQ

On which exchange is it traded?

Cleo Diagnostics Ltd is listed on CXA.

What is its stock symbol?

The ticker symbol is COV.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

Has Cleo Diagnostics Ltd ever had a stock split?

No, there has never been a stock split.

Cleo Diagnostics Ltd Profile

Health Care Technology Industry
Healthcare Sector
Dr. Richard Allman Ph.D. CEO
CXA Exchange
- ISIN
Australia Country
- Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Cleo Diagnostics Ltd is a pioneering medical diagnostics and devices company established in 2021 and headquartered in Melbourne, Australia. The core mission of Cleo Diagnostics is centered around the development and commercialization of non-invasive blood tests for the early detection of ovarian cancer. By focusing on innovative and accessible diagnostic solutions, the company aims to significantly improve early detection rates and outcomes for individuals at risk of ovarian cancer in Australia. Cleo Diagnostics is also dedicated to the advancement of its research and development efforts, working on securing intellectual property and patents to underpin its diagnostic technologies.

Products and Services

  • CleoDX Pre-Surgical Triage Tests
  • This cutting-edge diagnostic tool offered by Cleo Diagnostics represents a significant advancement in the management of ovarian cancer. The CleoDX test utilizes a proprietary combination of serum biomarkers to accurately assess the malignancy risk associated with ovarian tumors. Designed to be administered prior to surgical referral, this non-invasive blood test aims to improve the decision-making process for medical professionals, ensuring that patients receive the most appropriate level of care based on their individual risk assessment.

Contact Information

Address: 480 Collins Street
Phone: 61 3 9614 0600